CD276 and neoplasm: The counter receptor expressed on immune cells of B7H3 has not been identified yet, but it is conceivable that activated CD4+ and CD8+ T cells express a receptor interacting with APC cells or tumor cells through B7H3 and this interaction leads to inhibition of lymphocyte functions such as tumor cell killing and cytokine production (247–249).